News | European Medicines Agency (EMA)
EMA Management Board: highlights of October 2024 meeting. Board elects new vice-chair and endorses draft network strategy to 2028 for public consultation. 4 October 2024. Corporate Governance.
What's new - European Medicines Agency (EMA)
What’s new. Find all new and updated information published on our website in one place below. Filters are available to narrow results down based on your interests, such as whether it relates to human or veterinary medicines or specific topics. This overview covers up to two months back. Current month Previous month Two months ago.
European Medicines Agency (EMA)
Featured news and updated for European Academics and researchers in the field of medicine development. The European Medicines Agency is a decentralised agency of the European Union responsible for the evaluation, supervision and safety monitoring of medicines.
News and events | European Medicines Agency (EMA)
The European Medicines Agency's news announcements, information on meetings and events, public consultations and related information.
Newsletters - European Medicines Agency (EMA)
The European Medicines Agency (EMA) publishes newsletters to provide updates on various topics to patients, healthcare professionals and the pharmaceutical industry.
COVID-19: latest updates (archive) - European Medicines Agency …
EMA published updated information for COVID-19 Vaccine Valneva, with an increase in its approved shelf life. COVID-19 Vaccine (inactivated, adjuvanted) Valneva. 15/02/2023. The video recording is available of EMA's latest COVID-19 and …
Press and social media | European Medicines Agency (EMA)
The European Medicines Agency's (EMA) press office deals with enquiries from media on matters relating to the work of the Agency. EMA also manages a number of social-media platforms to raise awareness about its work on public and animal health …
Statement from Emer Cooke on the end of the COVID-19 public …
May 8, 2023 · On Friday, the WHO Director General declared an end to the Public Health Emergency of International Concern (PHEIC) for the disease caused by the coronavirus SARS-CoV-2. I welcome this important milestone and would like to share some thoughts about what this means for EMA.
Leqembi recommended for treatment of early Alzheimer’s disease
5 days ago · After re-examining its initial opinion, EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment (memory and thinking problems) or mild dementia due to Alzheimer’s disease (early Alzheimer’s disease) in patients who have only one or no copy of ...
Committee for Medicinal Products for Human Use (CHMP)
The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines. It plays a vital role in the authorisation of medicines in the European Union. The committee meets once a month. EMA publishes agendas, minutes and highlights of its plenary meetings.